Acute promyelocytic leukemia · 5 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Arsenic trioxide monotherapy Variant #01 | — | R 39 096 | 60d | — | — | ~6 | ~R 234 574 indirect | — |
ATRA, Mercaptopurine, Methotrexate Variant #01 | — | R 5 230 | 90d | — | — | ~26 | ~R 135 971 indirect | — |
ATRA monotherapy Variant #01 | — | R 3 613 | — | — | — | ~26 | ~R 93 927 indirect | — |
Mercaptopurine and Methotrexate Variant #05 | — | R 2 185 | 14d | — | — | ~26 | ~R 56 797 indirect | — |
Observation Partial | — | — | — | — | ~14.8 mo | — | — | — |
5 of 5 regimens shown